## Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 5

INVIVO THERAPEUTICS HOLDINGS CORP.

Form 5

January 22, 2016

<b>FORI</b>	15							OMB AF	PPROVAL	
UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB Number:	3235-0362	
Check thin no longer		vva	snington, D	.C. 2054:	9			Expires:	January 31 2005	
to Section 16. Form 4 or Form 5 obligations may continue.  ANNUAL STAT  OW			TEMENT OF CHANGES IN BENE WNERSHIP OF SECURITIES						ed average hours per	
See Instru 1(b). Form 3 H Reported Form 4 Transacti Reported	Filed purs  oldings Section 17(a	uant to Section 1 of the Public U 30(h) of the Ir	tility Holdin	g Compa	ny A	Act of 1	1935 or Sectio	n		
Lorianne Masuoka K. Syn IN			ssuer Name <b>and</b> Ticker or Trading hbol VIVO THERAPEUTICS DLDINGS CORP. [NVIV]				5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)			
(Last)				Duy/ I cur)				Director 10% Owner Selow)		
HOLDING	O THERAPEUTI S CORP., ONE L SQUARE, SUITI	CS					Chief	Medical Office	er	
	(Street)		endment, Date ( nth/Day/Year)	Original		6	6. Individual or Jo	oint/Group Rep		
CAMBRID	OGE, MA 02139	9								
CI IIVIBICID	GE,71 WI W 1 0213.	,				-	X_ Form Filed by Form Filed by I Person	One Reporting Po More than One Ro		
(City)	(State) (	Zip) Tab	le I - Non-Deri	vative Sec	uritie	es Acqui	ired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of Issuer's	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
				Amount	(A) or (D) Price		Fiscal Year (Instr. 3 and 4)			
Common Stock	12/31/2015	Â	A <u>(1)</u>	265	A	\$ 6.12	265	D	Â	
	port on a separate line seficially owned directly		contained in	n this for	m are	e not re	lection of infor	ond unless	SEC 2270 (9-02	

#### Edgar Filing: INVIVO THERAPEUTICS HOLDINGS CORP. - Form 5

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transaction	5. Number	6. Date Exerc Expiration D		7. Title Amou		8. Price of Derivative	
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ties	(Instr. 5)	
	Derivative				Securities			(Instr.	3 and 4)		
	Security				Acquired						
	•				(A) or						
					Disposed						
					of (D)						
					(Instr. 3,						
					4, and 5)						
									Amount		
									or		
						Date	Expiration		Number		
						Exercisable	Date		of		
					(A) (D)				Shares		
					$(\Delta)$				Shares		

D So

### **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Lorianne Masuoka K. C/O INVIVO THERAPEUTICS HOLDINGS CORP. ONE KENDALL SQUARE, SUITE B14402 CAMBRIDGE Â MA Â 02139	Â	Â	Chief Medical Officer	Â	

#### **Signatures**

/s/ Elizabeth W. Fraser, Attorney-in-Fact

01/22/2016

\*\*Signature of Reporting Person

Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These shares were acquired under the Issuer's Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2